NASDAQ:ALBT Avalon GloboCare (ALBT) Stock Price, News & Analysis $0.40 -0.02 (-4.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.40▼$0.4350-Day Range$0.28▼$1.2352-Week Range$0.24▼$1.46Volume50,409 shsAverage Volume1.32 million shsMarket Capitalization$4.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Avalon GloboCare alerts: Email Address Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Avalon GloboCare Stock (NASDAQ:ALBT)Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Read More ALBT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALBT Stock News HeadlinesJuly 26 at 5:40 AM | americanbankingnews.comAvalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Down 48.1% in JulyJune 20, 2024 | proactiveinvestors.comAvalon GloboCare unveils KetoAir breathalyzer at KetoCon 2024July 26, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.June 4, 2024 | investorplace.comWhy Is Avalon Globocare (ALBT) Stock Down 27% Today?May 24, 2024 | finance.yahoo.comAvalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly ReportMay 24, 2024 | globenewswire.comAvalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly ReportApril 25, 2024 | finance.yahoo.comAvalon GloboCare Corp. (ALBT)April 23, 2024 | proactiveinvestors.comAvalon GloboCare launches KetoAir breathalyzer in the USJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” April 22, 2024 | globenewswire.comAvalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 ConferenceApril 16, 2024 | msn.comALBT Stock Earnings: Avalon Globocare Reported Results for Q4 2023March 28, 2024 | proactiveinvestors.comAvalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzerMarch 28, 2024 | globenewswire.comAvalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European UnionDecember 18, 2023 | finance.yahoo.comAvalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the USNovember 16, 2023 | morningstar.comAvalon Globocare Corp ALBTOctober 18, 2023 | finance.yahoo.comAvalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic KetoacidosisOctober 6, 2023 | benzinga.comApple Approves Use of Avalon GloboCare's KetoAir Mobile ApplicationOctober 6, 2023 | finance.yahoo.comShareholders May Be A Bit More Conservative With Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation For NowSee More Headlines Receive ALBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalon GloboCare and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/30/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALBT CUSIPN/A CIK1630212 Webwww.avalon-globocare.com Phone(732) 780-4400Fax732-780-5600Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,710,000.00 Net Margins-1,173.55% Pretax Margin-1,189.56% Return on EquityN/A Return on Assets-58.95% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.10 Sales & Book Value Annual Sales$1.26 million Price / Sales3.56 Cash FlowN/A Price / Cash FlowN/A Book Value($1.15) per share Price / Book-0.35Miscellaneous Outstanding Shares11,100,000Free Float3,998,000Market Cap$4.49 million OptionableNot Optionable Beta0.32 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. David K. Jin M.D. (Age 56)Ph.D., CEO, President & Director Comp: $330kMs. Luisa Ingargiola (Age 57)Chief Financial Officer Comp: $350kMs. Meng Li (Age 46)COO, Chief Marketing Officer & Secretary Comp: $280.24kKey CompetitorsATIFNASDAQ:ATIFRyvylNASDAQ:RVYLPharmaCyte BiotechNASDAQ:PMCBEvaxion Biotech A/SNASDAQ:EVAXAptose BiosciencesNASDAQ:APTOView All Competitors ALBT Stock Analysis - Frequently Asked Questions How have ALBT shares performed this year? Avalon GloboCare's stock was trading at $0.4830 at the start of the year. Since then, ALBT stock has decreased by 16.3% and is now trading at $0.4045. View the best growth stocks for 2024 here. How were Avalon GloboCare's earnings last quarter? Avalon GloboCare Corp. (NASDAQ:ALBT) issued its earnings results on Thursday, May, 30th. The company reported ($0.12) EPS for the quarter. The company had revenue of $0.32 million for the quarter. When did Avalon GloboCare's stock split? Shares of Avalon GloboCare reverse split before market open on Tuesday, January 3rd 2023. The 1-10 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Avalon GloboCare? Shares of ALBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALBT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
